65 下列屬於 Triptans 類之藥品中,何者與 CYP3A4 抑制劑具有最顯著之交互作用,應避免合併使用?
(A) Eletriptan
(B) Rizatriptan
(C) Zolmitriptan
(D) Frovatriptan
答案:登入後查看
統計: A(770), B(499), C(443), D(122), E(0) #411256
統計: A(770), B(499), C(443), D(122), E(0) #411256
詳解 (共 5 筆)
#896228
(A) Eletriptan:3A4 排除
(B) Rizatriptan:MAO-A 排除
(C) Zolmitriptan:MAO-A , 1A2 排除
(D) Frovatriptan:1A2 排除
(B) Rizatriptan:MAO-A 排除
(C) Zolmitriptan:MAO-A , 1A2 排除
(D) Frovatriptan:1A2 排除
94
0
#2900832
Sumatriptan 經MAO-A代謝、不經過CYP450
25
0
#5504699
Inhibitors of cytochrome P-450 (CYP) 3A4 reduce the clearance of almotriptan and eletriptan. For almotriptan, increased exposure to triptans should be anticipated; however, no specific dosing adjustments are proposed. The interaction between eletriptan and CYP 3A4 inhibitors is more significant, and particular precautions are necessary. Eletriptan should not be used within 72 hours of treatment with potent CYP 3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir).
Applied 10e p1345
Applied 10e p1345
1
0